2023 ASCO Annual Meeting

Share on: 

Research coauthored by RTI Health Solutions experts will be presented online at the 2023 ASCO Annual Meeting.

Treatment patterns of triple-class refractory (TCR) multiple myeloma (MM) across the United States (US), Canada, and western Europe: a real-world observational chart review study. Goyal RK, Frugier G, Rombi J, Esterberg L, Davis KL, Hlavacek P, Ren J, Schepart A, Aydin D, DeBonaventura M.

Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): 36-month results of nivolumab plus chemotherapy (N+C) versus (C) from CheckMate 649. Elimova E, Wyrwicz L, Chen C, Blum SM, Davenport E, Wang J, Kondo K, Moehler MH.

Real-world assessment of treatment effectiveness in patients with advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping (METex14). Furqan M, Karanth S, Goyal RK, Shih Y, Cai B, Rombi J, Davis KL, Caro N, Saliba TR.